Lv44
480 积分 2022-02-15 加入
Antibody–Exatecan Conjugates with a Novel Self-immolative Moiety Overcome Resistance in Colon and Lung Cancer
1小时前
待确认
SPARC: A Multipayload ADC Architecture for Programmable Drug Combinations
2天前
已完结
Effect of Liraglutide on Fat Mass Percentage Among Overweight and Obese Adults with Type 2 Diabetes: A Systematic Review
11天前
已完结
IL-2Rα-biased agonist enhances antitumor immunity by invigorating tumor-infiltrating CD25+CD8+ T cells
1个月前
已完结
A Phase 1b Study of Ivonescimab, a Programmed Cell Death Protein-1 and Vascular Endothelial Growth Factor Bispecific Antibody, as First- or Second-Line Therapy for Advanced or Metastatic Immunotherapy-Naive NSCLC
1个月前
已完结
Antibody–Exatecan Conjugates with a Novel Self-immolative Moiety Overcome Resistance in Colon and Lung Cancer
2个月前
已完结
Strategies and Recommendations for Using a Data‐Driven and Risk‐Based Approach in the Selection of First‐in‐Human Starting Dose: An International Consortium for Innovation and Quality in Pharmaceutical Development (IQ) Assessment
3个月前
已完结
The use of recovery animals in nonclinical safety assessment studies with monoclonal antibodies: further 3Rs opportunities remain
3个月前
已完结
Development and characterization of NILK-2301, a novel CEACAM5xCD3 κλ bispecific antibody for immunotherapy of CEACAM5-expressing cancers
4个月前
已完结
IBCL-482: Fixed-Duration Subcutaneous Mosunetuzumab (Mosun SC) Leads to High Rates of Durable Responses, Low Rates of Cytokine Release Syndrome (CRS), and Non-Inferior Exposure Compared With Intravenous Administration in Patients With Relapsed/Refractory (R/R) Follicular Lymphoma (FL): Primary Analysis of a Pivotal Phase 2 Study
4个月前
已关闭
皖公网安备34019202002308
